1. Home
  2. GRX vs IPHA Comparison

GRX vs IPHA Comparison

Compare GRX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Gabelli Healthcare & Wellness Trust of Beneficial Interest

GRX

The Gabelli Healthcare & Wellness Trust of Beneficial Interest

HOLD

Current Price

$9.07

Market Cap

132.9M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.49

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRX
IPHA
Founded
N/A
1999
Country
United States
France
Employees
N/A
163
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.9M
131.4M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
GRX
IPHA
Price
$9.07
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
19.8K
20.9K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.93
$1.18
52 Week High
$10.05
$2.63

Technical Indicators

Market Signals
Indicator
GRX
IPHA
Relative Strength Index (RSI) 40.16 51.87
Support Level $8.93 $1.18
Resistance Level $9.35 $1.80
Average True Range (ATR) 0.12 0.08
MACD 0.01 -0.01
Stochastic Oscillator 2.93 35.00

Price Performance

Historical Comparison
GRX
IPHA

About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest

Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: